尼拉帕利治疗转移性去势抵抗性前列腺癌伴DNA修复基因缺陷患者(GALAHAD):多中心、开放标签、2期试验
GALAHAD是一项多中心、开放标签、单臂2期研究,评估PARP抑制剂尼拉帕利在既往接受过雄激素信号抑制剂和紫杉烷治疗后进展的转移性去势抵抗性前列腺癌伴DNA修复基因缺陷患者中的抗肿瘤活性和安全性。可测量BRCA队列(n=76)的客观缓解率为34.2%(95%CI 23.7-46.0)。尼拉帕利耐受性可,在重度经治患者中显示出抗肿瘤活性,尤其在BRCA改变者中。
要点
- 可测量BRCA队列(n=76)客观缓解率为34.2%(95%CI 23.7-46.0)。
- 最常见任何级别治疗中出现的不良事件为恶心(58%)、贫血(54%)和呕吐(38%)。
- 最常见≥3级不良事件为血液学毒性:贫血33%、血小板减少16%、中性粒细胞减少10%。
核心结论
- 尼拉帕利耐受性可,在重度经治的转移性去势抵抗性前列腺癌伴DNA修复基因缺陷患者中显示出抗肿瘤活性,尤其在BRCA改变者中。
研究设计与样本
- 多中心、开放标签、单臂2期研究,纳入年龄≥18岁、组织学确诊的转移性去势抵抗性前列腺癌(除外纯小细胞表型)且存在DNA修复基因缺陷的患者。
- 患者既往接受过下一代雄激素信号抑制剂和紫杉烷治疗后进展,ECOG体能状态0-2,接受尼拉帕利300 mg口服每日一次直至治疗中止、死亡或研究终止。
- 安全性分析纳入所有至少接受一剂研究药物的患者;疗效分析纳入BRCA1或BRCA2胚系致病性或体细胞双等位基因致病性改变(BRCA队列)或其他预设DNA修复基因缺陷双等位基因改变(非BRCA队列)的患者。
- 主要终点为BRCA改变且可测量疾病患者(可测量BRCA队列)的客观缓解率;研究注册号ClinicalTrials.gov NCT02854436。
主要发现
- 2016年9月28日至2020年6月26日共入组289例患者,其中182例(63%)曾接受≥3种前列腺癌全身治疗。
- 289例中223例(77%)纳入总体疗效分析人群,包括BRCA队列(n=142)和非BRCA队列(n=81)。
- 最终分析时中位随访10.0个月(IQR 6.6-13.3),可测量BRCA队列(n=76)的客观缓解率为34.2%(95%CI 23.7-46.0)。
- 安全性分析人群中,任何级别最常见治疗中出现的不良事件为恶心(289例中169例[58%])、贫血(156例[54%])和呕吐(111例[38%]);最常见≥3级事件为血液学毒性:贫血(289例中95例[33%])、血小板减少(47例[16%])和中性粒细胞减少(28例[10%])。
- 289例中134例(46%)发生至少一次严重治疗中出现的不良事件,最常见亦为血液学毒性:血小板减少(17例[6%])和贫血(13例[4%]);2例不良事件导致死亡(BRCA队列1例尿脓毒症,非BRCA队列1例脓毒症),被认为可能与尼拉帕利治疗相关。
关键数值与推荐
- 可测量BRCA队列(n=76)客观缓解率为34.2%(95%CI 23.7-46.0)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic castration-resistant prostate cancers are enriched for DNA repair gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP proteins. We evaluated the anti-tumour activity and safety of the PARP inhibitor niraparib in patients with metastatic castration-resistant prostate cancers and DRDs who progressed on previous treatment with an androgen signalling inhibitor and a taxane. METHODS: In this multicentre, open-label, single-arm, phase 2 study, patients aged at least 18 years with histologically confirmed metastatic castration-resistant prostate cancer (mixed histology accepted, with the exception of the small cell pure phenotype) and DRDs (assessed in blood, tumour tissue, or saliva), with progression on a previous next-generation androgen signalling inhibitor and a taxane per Response Evaluation Criteria in Solid Tumors 1.1 or Prostate Cancer Working Group 3 criteria and an Eastern Cooperative Oncology Group performance status of 0-2, were eligible. Enrolled patients received niraparib 300 mg orally once daily until treatment discontinuation, death, or study termination. For the final study analysis, all patients who received at least one dose of study drug were included in the safety analysis population; patients with germline pathogenic or somatic biallelic pathogenic alterations in BRCA1 or BRCA2 (BRCA cohort) or biallelic alterations in other prespecified DRDs (non-BRCA cohort) were included in the efficacy analysis population. The primary endpoint was objective response rate in patients with BRCA alterations and measurable disease (measurable BRCA cohort). This study is registered with ClinicalTrials.gov, NCT02854436. FINDINGS: Between Sept 28, 2016, and June 26, 2020, 289 patients were enrolled, of whom 182 (63%) had received three or more systemic therapies for prostate cancer. 223 (77%) of 289 patients were included in the overall efficacy analysis population, which included BRCA (n=142) and non-BRCA (n=81) cohorts. At final analysis, with a median follow-up of 10·0 months (IQR 6·6-13·3), the objective response rate in the measurable BRCA cohort (n=76) was 34·2% (95% CI 23·7-46·0). In the safety analysis population, the most common treatment-emergent adverse events of any grade were nausea (169 [58%] of 289), anaemia (156 [54%]), and vomiting (111 [38%]); the most common grade 3 or worse events were haematological (anaemia in 95 [33%] of 289; thrombocytopenia in 47 [16%]; and neutropenia in 28 [10%]). Of 134 (46%) of 289 patients with at least one serious treatment-emergent adverse event, the most common were also haematological (thrombocytopenia in 17 [6%] and anaemia in 13 [4%]). Two adverse events with fatal outcome (one patient with urosepsis in the BRCA cohort and one patient with sepsis in the non-BRCA cohort) were deemed possibly related to niraparib treatment. INTERPRETATION: Niraparib is tolerable and shows anti-tumour activity in heavily pretreated patients with metastatic castration-resistant prostate cancer and DRDs, particularly in those with BRCA alterations. FUNDING: Janssen Research & Development.
引用
- Smith MR, Scher HI, Sandhu S, et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022. PMID: 35131040. doi:10.1016/S1470-2045(21)00757-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。